Cargando…
A feasibility study of the burden of disease of atopic dermatitis using a smartphone research application, myEczema
BACKGROUND: Our understanding of chronic diseases, such as atopic dermatitis (AD), could benefit from the ability to rapidly collect patient-reported, longitudinal data from a large population. OBJECTIVE: This study aimed to determine whether a smartphone app can be used to collect demographic and l...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060681/ https://www.ncbi.nlm.nih.gov/pubmed/33898712 http://dx.doi.org/10.1016/j.ijwd.2020.08.001 |
Sumario: | BACKGROUND: Our understanding of chronic diseases, such as atopic dermatitis (AD), could benefit from the ability to rapidly collect patient-reported, longitudinal data from a large population. OBJECTIVE: This study aimed to determine whether a smartphone app can be used to collect demographic and longitudinal symptom data and recognize prescribing patterns and affordability of medications to study the burden of AD. METHODS: We collected data using the myEczema smartphone app between July 2017 and April 2018. The data were de-identified and analyzed. RESULTS: A total of 519 users (94.2%) completed the initial demographic survey. The majority of users were female (n = 387; 70.2%) and Caucasian (n = 358; 65.0%). A total of 335 users (60.8%) had at least a university degree and were employed (n = 348; 63.1%). A total of 189 users (29.2%) reported difficulty affording their medications, and 363 users (65.9%) took advantage of the itch score recording feature. Finally, 184 users (33.4%) logged their treatments, with the highest number of users (65.2%) listing topical steroids as one of their treatments. LIMITATIONS: The operating platform was limited to iPhones, and the results were subject to reporting bias. CONCLUSION: A smartphone-based research app can be used to rapidly collect patient-reported data to study the burden of AD and to highlight the prescribing patterns and affordability of medications. |
---|